Last reviewed: June 11, 2026
Last updated: June 11, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Mounjaro and semaglutide are often mentioned together in weight loss conversations, but they are chemically distinct medications. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors, while semaglutide targets only the GLP-1 receptor. This fundamental difference affects how each drug works in the body and which patients may benefit most from each option.
What Is Mounjaro and How Does It Differ From Semaglutide?
Mounjaro is a brand-name tirzepatide injection developed by Eli Lilly for weight management and type 2 diabetes. Unlike semaglutide, which activates a single receptor pathway, tirzepatide is a dual GLP-1 and GIP receptor agonist. This dual mechanism means tirzepatide influences appetite regulation, insulin secretion, and glucose control through two separate biochemical pathways simultaneously. The distinction matters because patients may respond differently to single-receptor versus dual-receptor medications based on their individual metabolic makeup.
Semaglutide, marketed as Ozempic or Wegovy, works exclusively through GLP-1 receptor activation. While GLP-1 therapy has proven effective for millions, the addition of GIP activation in tirzepatide creates a complementary effect that some patients find more effective for weight reduction and metabolic improvement. Clinical trials have shown tirzepatide produces greater average weight loss than GLP-1-only medications in head-to-head comparisons, though individual results vary widely based on genetics and lifestyle factors.
How Tirzepatide Works: The Dual-Receptor Advantage
Tirzepatide activates two hormone receptors that control hunger, fullness signals, and blood sugar metabolism. The GLP-1 receptor slows gastric emptying and increases satiety, while the GIP receptor enhances insulin release and may improve energy expenditure. Together, these mechanisms create a more comprehensive metabolic effect than single-pathway therapy alone. This dual action can result in faster appetite suppression and sustained weight loss in responsive patients.
The GIP receptor pathway has been largely unexploited in weight loss medications until tirzepatide's arrival, making it a novel approach to metabolic management. Research published in clinical obesity journals demonstrates that GIP activation synergizes with GLP-1 effects, particularly in patients with insulin resistance or metabolic syndrome. PlexusDx's Precision Peptide Genetic Test can identify genetic variants in the GIPR gene that may predict how strongly an individual will respond to tirzepatide therapy, allowing for truly personalized treatment selection.
Clinical Evidence: Tirzepatide Outcomes vs Semaglutide Results
Major clinical trials comparing tirzepatide to semaglutide show consistent advantages for dual-receptor therapy in weight reduction metrics. The SURMOUNT trials demonstrated that tirzepatide users achieved weight loss ranging from 15% to 22% of baseline body weight depending on dose, compared to approximately 10-17% for semaglutide users over similar timeframes. These differences become more pronounced in patients with baseline BMI above 35 or those with concurrent type 2 diabetes requiring robust glycemic control.
However, superiority in clinical trials does not guarantee superiority for every individual patient. Some patients achieve excellent results with semaglutide alone, while others require tirzepatide's dual action to reach their goals. This is why genetic testing and metabolic assessment matter: they help match patients to the therapy most likely to work with their unique biology. PlexusDx evaluates 150+ genetic insights across 14 metabolic pathways to guide this personalized selection process.
Compounded Tirzepatide at PlexusDx: Affordable Access Without Compromise
PlexusDx offers compounded tirzepatide injection starting at $249/month through licensed 503A compounding pharmacies, providing medical-grade peptide therapy without the brand-name premium. Compounding allows for flexible dosing schedules and customization not always available through retail pharmacies, and PlexusDx eliminates insurance barriers—no coverage required, no membership fees. All medications are prepared under strict pharmaceutical standards and are HSA/FSA eligible, making personalized peptide therapy accessible to motivated patients across all 50 states.
The pricing model at PlexusDx follows a simple commitment-tier structure: your dose may need to go up over time as your body adapts, but your price won't. Tirzepatide compounded injections remain $249/month across all dose levels, whether you start at 2.5 mg weekly or advance to 15 mg. For patients who prefer oral delivery, oral tirzepatide begins at $279/month. This transparent, flat-rate approach removes the guesswork from long-term treatment budgeting and ensures cost never becomes a barrier to dose optimization.
The Role of Genetic Testing in Choosing Between Tirzepatide and Semaglutide
PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) analyzes key genetic variants that predict peptide-pathway responsiveness, including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These variants influence how aggressively your body responds to tirzepatide's GIP activation, your baseline GLP-1 sensitivity, and your genetic predisposition to weight regain. Testing reveals which peptide pathway—single or dual—aligns best with your metabolic biology, reducing trial-and-error experimentation.
Patients with specific GLP1R variants may achieve excellent outcomes with semaglutide alone, while those with particular GIPR variants often show stronger responses to tirzepatide's dual mechanism. Testing maps 49 different peptides across 14 biochemical pathways, providing your PlexusDx clinician with data-driven guidance for treatment selection and dose progression. This precision approach transforms weight loss from a one-size-fits-all intervention into a truly personalized metabolic strategy grounded in your genetic predispositions.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Mounjaro the same as semaglutide?
No. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist, while semaglutide activates only the GLP-1 receptor. This fundamental chemical difference creates distinct metabolic effects and may produce different weight loss outcomes depending on individual genetics and baseline metabolism.
Does tirzepatide work better than semaglutide for weight loss?
Clinical trials show tirzepatide produces greater average weight loss (15-22% of baseline) compared to semaglutide (10-17% of baseline) in most populations. However, individual responses vary significantly based on genetic factors, insulin sensitivity, and metabolic health. PlexusDx's Precision Peptide Genetic Test identifies your personal response predictors to guide optimal medication selection.
How much does compounded tirzepatide cost at PlexusDx?
PlexusDx compounded tirzepatide injection starts at $249/month and remains at that flat rate across all dose levels—your dose may go up, but your price won't. The service is available nationwide without insurance requirements, and treatment is HSA/FSA eligible for additional savings.
What are the differences in side effects between tirzepatide and semaglutide?
Both medications share common GLP-1 side effects like nausea, vomiting, and constipation, particularly during initial weeks. Tirzepatide may cause additional GIP-related effects in some patients, though most side effects diminish as the body adapts. PlexusDx clinicians monitor tolerance and adjust dosing schedules to minimize discomfort while maintaining therapeutic benefit.
Can genetic testing help me decide between tirzepatide and semaglutide?
Yes. PlexusDx's Precision Peptide Genetic Test analyzes variants in GIPR, GLP1R, FTO, and MC4R genes that predict your responsiveness to dual-receptor versus single-receptor therapy. Testing costs $99 after your first month and reveals which peptide pathway your body will respond to most strongly, enabling truly personalized treatment selection.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Do You Prime Ozempic Pen Every Time? What You Need to Know for Safe and Effective Use
How Much Weight Can You Expect to Lose on Ozempic?